<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Front Pharmacol</journal-id><journal-id journal-id-type="iso-abbrev">Front Pharmacol</journal-id><journal-id journal-id-type="publisher-id">Front. Pharmacol.</journal-id><journal-title-group><journal-title>Frontiers in Pharmacology</journal-title></journal-title-group><issn pub-type="epub">1663-9812</issn><publisher><publisher-name>Frontiers Media S.A.</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">28701958</article-id><article-id pub-id-type="pmc">5487530</article-id><article-id pub-id-type="doi">10.3389/fphar.2017.00423</article-id><article-categories><subj-group subj-group-type="heading"><subject>Pharmacology</subject><subj-group><subject>Original Research</subject></subj-group></subj-group></article-categories><title-group><article-title>A Single Dose of LSD Does Not Alter Gene Expression of the Serotonin 2A Receptor Gene (<italic>HTR2A</italic>) or Early Growth Response Genes (<italic>EGR1-3</italic>) in Healthy Subjects</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Dolder</surname><given-names>Patrick C.</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Gr&#x000fc;nblatt</surname><given-names>Edna</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff3"><sup>3</sup></xref><xref ref-type="aff" rid="aff4"><sup>4</sup></xref><uri xlink:type="simple" xlink:href="http://loop.frontiersin.org/people/383363/overview"/></contrib><contrib contrib-type="author"><name><surname>M&#x000fc;ller</surname><given-names>Felix</given-names></name><xref ref-type="aff" rid="aff5"><sup>5</sup></xref></contrib><contrib contrib-type="author"><name><surname>Borgwardt</surname><given-names>Stefan J.</given-names></name><xref ref-type="aff" rid="aff5"><sup>5</sup></xref><uri xlink:type="simple" xlink:href="http://loop.frontiersin.org/people/67251/overview"/></contrib><contrib contrib-type="author"><name><surname>Liechti</surname><given-names>Matthias E.</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="author-notes" rid="fn001"><sup>*</sup></xref><uri xlink:type="simple" xlink:href="http://loop.frontiersin.org/people/89701/overview"/></contrib></contrib-group><aff id="aff1"><sup>1</sup><institution>Division of Clinical Pharmacology and Toxicology, Department of Biomedicine and Department of Clinical Research, University Hospital Basel and University of Basel</institution><country>Basel, Switzerland</country></aff><aff id="aff2"><sup>2</sup><institution>Department of Child and Adolescent Psychiatry and Psychotherapy, Psychiatric Hospital, University of Zurich</institution><country>Zurich, Switzerland</country></aff><aff id="aff3"><sup>3</sup><institution>Neuroscience Center Zurich, University of Zurich and ETH Zurich</institution><country>Zurich, Switzerland</country></aff><aff id="aff4"><sup>4</sup><institution>Zurich Center for Integrative Human Physiology, University of Zurich</institution><country>Zurich, Switzerland</country></aff><aff id="aff5"><sup>5</sup><institution>Department of Psychiatry (Universit&#x000e4;re Psychiatrische Kliniken Basel), University of Basel</institution><country>Basel, Switzerland</country></aff><author-notes><fn fn-type="edited-by"><p>Edited by: <italic>Andrew Robert Gallimore, Okinawa Institute of Science and Technology, Japan</italic></p></fn><fn fn-type="edited-by"><p>Reviewed by: <italic>Attila Szabo, University of Oslo, Norway; Jean-Philippe Guilloux, Universit&#x000e9; Paris-Sud, France</italic></p></fn><corresp id="fn001">*Correspondence: <italic>Matthias E. Liechti, <email xlink:type="simple">matthias.liechti@usb.ch</email></italic></corresp><fn fn-type="other" id="fn002"><p>This article was submitted to Neuropharmacology, a section of the journal Frontiers in Pharmacology</p></fn></author-notes><pub-date pub-type="epub"><day>28</day><month>6</month><year>2017</year></pub-date><pub-date pub-type="collection"><year>2017</year></pub-date><volume>8</volume><elocation-id>423</elocation-id><history><date date-type="received"><day>20</day><month>4</month><year>2017</year></date><date date-type="accepted"><day>14</day><month>6</month><year>2017</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2017 Dolder, Gr&#x000fc;nblatt, M&#x000fc;ller, Borgwardt and Liechti.</copyright-statement><copyright-year>2017</copyright-year><copyright-holder>Dolder, Gr&#x000fc;nblatt, M&#x000fc;ller, Borgwardt and Liechti</copyright-holder><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</license-p></license></permissions><abstract><p><bold>Rationale:</bold> Renewed interest has been seen in the use of lysergic acid diethylamide (LSD) in psychiatric research and practice. The repeated use of LSD leads to tolerance that is believed to result from serotonin (5-HT) 5-HT<sub>2A</sub> receptor downregulation. In rats, daily LSD administration for 4 days decreased frontal cortex 5-HT<sub>2A</sub> receptor binding. Additionally, a single dose of LSD acutely increased expression of the early growth response genes <italic>EGR1</italic> and <italic>EGR2</italic> in rat and mouse brains through 5-HT<sub>2A</sub> receptor stimulation. No human data on the effects of LSD on gene expression has been reported. Therefore, we investigated the effects of single-dose LSD administration on the expression of the 5-HT<sub>2A</sub> receptor gene (<italic>HTR2A</italic>) and <italic>EGR1-3</italic> genes.</p><p><bold>Methods:</bold> mRNA expression levels were analyzed in whole blood as a peripheral biomarker in 15 healthy subjects before and 1.5 and 24 h after the administration of LSD (100 &#x003bc;g) and placebo in a randomized, double-blind, placebo-controlled, cross-over study.</p><p><bold>Results:</bold> LSD did not alter the expression of the <italic>HTR2A</italic> or <italic>EGR1-3</italic> genes 1.5 and 24 h after administration compared with placebo.</p><p><bold>Conclusion:</bold> No changes were observed in the gene expression of LSD&#x02019;s primary target receptor gene or genes that are implicated in its downstream effects. Remaining unclear is whether chronic LSD administration alters gene expression in humans.</p></abstract><kwd-group><kwd>LSD</kwd><kwd>serotonin receptor</kwd><kwd>gene expression</kwd><kwd>healthy subjects</kwd></kwd-group><funding-group><award-group><funding-source id="cn001">Schweizerischer Nationalfonds zur F&#x000f6;rderung der Wissenschaftlichen Forschung<named-content content-type="fundref-id">10.13039/501100001711</named-content></funding-source><award-id rid="cn001">320030_170249</award-id></award-group><award-group><funding-source id="cn002">Universit&#x000e4;t Basel<named-content content-type="fundref-id">10.13039/100008375</named-content></funding-source><award-id rid="cn002">to FM</award-id></award-group></funding-group><counts><fig-count count="1"/><table-count count="2"/><equation-count count="0"/><ref-count count="53"/><page-count count="7"/><word-count count="0"/></counts></article-meta></front><body><sec><title>Introduction</title><p>Lysergic acid diethylamide (LSD) is a well-known psychoactive substance that transiently alters mind and perception. During the last few years, renewed interest has been seen in the use of LSD in psychiatric research and practice (<xref rid="B28" ref-type="bibr">Liechti, 2017</xref>). Modern experimental studies in humans have reported LSD&#x02019;s subjective, autonomic, and endocrine effects (<xref rid="B44" ref-type="bibr">Schmid et al., 2015</xref>; <xref rid="B7" ref-type="bibr">Carhart-Harris et al., 2016a</xref>; <xref rid="B14" ref-type="bibr">Dolder et al., 2016</xref>; <xref rid="B47" ref-type="bibr">Strajhar et al., 2016</xref>; <xref rid="B29" ref-type="bibr">Liechti et al., 2017</xref>), functional brain activation patterns (<xref rid="B8" ref-type="bibr">Carhart-Harris et al., 2016b</xref>; <xref rid="B27" ref-type="bibr">Lebedev et al., 2016</xref>; <xref rid="B49" ref-type="bibr">Tagliazucchi et al., 2016</xref>; <xref rid="B39" ref-type="bibr">Preller et al., 2017</xref>), and pharmacokinetics (<xref rid="B13" ref-type="bibr">Dolder et al., 2015b</xref>, <xref rid="B15" ref-type="bibr">2017</xref>). However, many aspects of LSD&#x02019;s pharmacological effects remain unclear, including the phenomenon of the rapid development of tolerance (i.e., tachyphylaxis) to its psychological and physiological effects with repeated administration (<xref rid="B38" ref-type="bibr">Passie et al., 2008</xref>). Early studies that employed repeated daily administration of 100 &#x003bc;g LSD in humans described partial tolerance with the second dose and complete tolerance with the third and subsequent doses (<xref rid="B10" ref-type="bibr">Cholden et al., 1955</xref>; <xref rid="B1" ref-type="bibr">Abramson et al., 1956</xref>; <xref rid="B2" ref-type="bibr">Belleville et al., 1956</xref>). The effects of LSD reappeared only after a substance-free interval of 4 days. Tolerance to LSD is believed to result from serotonin 5-HT<sub>2A</sub> receptor downregulation (<xref rid="B37" ref-type="bibr">Nichols, 2016</xref>). LSD potently binds to the 5-HT<sub>2A</sub> receptor (<xref rid="B52" ref-type="bibr">Wacker et al., 2017</xref>) where it acts as a partial agonist (<xref rid="B41" ref-type="bibr">Rickli et al., 2016</xref>). Pretreatment with the 5-HT<sub>2A</sub> receptor antagonist ketanserin completely prevented all perceptual and mind-altering effects of LSD in humans (<xref rid="B26" ref-type="bibr">Kraehenmann et al., 2017</xref>; <xref rid="B39" ref-type="bibr">Preller et al., 2017</xref>), indicating that the hallucinogenic effects of LSD are primarily mediated through 5-HT<sub>2A</sub> receptors. Similar to humans, tolerance to the behavioral effects of LSD is also observed in rats (<xref rid="B4" ref-type="bibr">Buchborn et al., 2015</xref>). Consistent with a role for 5-HT<sub>2A</sub> receptors in the development of tolerance, daily LSD administration for 3 days decreased 5-HT<sub>2A</sub> receptor binding in the rat frontal cortex (<xref rid="B5" ref-type="bibr">Buckholtz et al., 1985</xref>, <xref rid="B6" ref-type="bibr">1990</xref>; <xref rid="B21" ref-type="bibr">Gresch et al., 2005</xref>). However, another study reported only a non-significant trend toward a reduction of frontocortical 5-HT<sub>2A</sub> receptor binding in rats during the development of tolerance to LSD (<xref rid="B4" ref-type="bibr">Buchborn et al., 2015</xref>). Additionally, no effects of acute LSD on 5-HT<sub>2A</sub> receptor mRNA expression were found in the rat prefrontal cortex, hippocampus, or midbrain (<xref rid="B35" ref-type="bibr">Nichols and Sanders-Bush, 2002</xref>), although the effects of repeated LSD administration were not studied. Instead, adaptations in glutamate receptors were observed (<xref rid="B4" ref-type="bibr">Buchborn et al., 2015</xref>). Indeed, a key mechanism of action of LSD is the activation of frontal cortex glutamate transmission secondary to 5-HT<sub>2A</sub> receptor stimulation (<xref rid="B18" ref-type="bibr">Gonzalez-Maeso et al., 2008</xref>; <xref rid="B33" ref-type="bibr">Moreno et al., 2011</xref>; <xref rid="B4" ref-type="bibr">Buchborn et al., 2015</xref>). Thus, adaptive changes that underlie tolerance to LSD may be reflected by alterations in the expression of genes that are involved in glutamatergic signaling or genes that regulate 5-HT<sub>2A</sub> receptor function or its downstream signaling pathways. Acute LSD increased the expression of immediate early genes in the rat prefrontal cortex, including <italic>EGR2</italic> (i.e., a gene that is involved in cognition and neural plasticity) and several others genes (<xref rid="B35" ref-type="bibr">Nichols and Sanders-Bush, 2002</xref>; <xref rid="B34" ref-type="bibr">Nichols et al., 2003</xref>; <xref rid="B36" ref-type="bibr">Nichols and Sanders-Bush, 2004</xref>). Further animal studies showed that LSD also increased the expression of <italic>EGR2</italic> and <italic>EGR1</italic> in the mouse cortex via 5-HT<sub>2A</sub> receptor stimulation (<xref rid="B20" ref-type="bibr">Gonzalez-Maeso et al., 2003</xref>, <xref rid="B19" ref-type="bibr">2007</xref>). Finally, LSD was shown to produce a characteristic transcriptome signaling pattern in normal but not <italic>HTR2A</italic><sup>-/-</sup> mice (<xref rid="B19" ref-type="bibr">Gonzalez-Maeso et al., 2007</xref>).</p><p>Despite the renewed interest in the clinical use of LSD, no human studies on the effects of LSD on gene expression have been performed. Therefore, we investigated the effects of a single dose of LSD on the expression of the 5-HT<sub>2A</sub> receptor gene (<italic>HTR2A</italic>) and <italic>EGR1-3</italic> genes. The <italic>EGR1</italic> and <italic>EGR2</italic> genes were studied based on preclinical data (<xref rid="B20" ref-type="bibr">Gonzalez-Maeso et al., 2003</xref>, <xref rid="B19" ref-type="bibr">2007</xref>), and the <italic>EGR3</italic> gene was studied because it has been shown to regulate <italic>HTR2A</italic> expression (<xref rid="B31" ref-type="bibr">Maple et al., 2015</xref>).</p><p>Acute changes in gene expression cannot be determined in heathy human brain tissue, as biopsy or postmortem tissue is not available. However, mRNA level changes in blood for candidate genes including <italic>EGR</italic> and <italic>HTR2A</italic> can cautiously be used as peripheral markers of transcription alterations in the CNS in response to interventions or to characterize patient groups (<xref rid="B48" ref-type="bibr">Sullivan et al., 2006</xref>; <xref rid="B32" ref-type="bibr">Mohr and Liew, 2007</xref>; <xref rid="B11" ref-type="bibr">Desjardins et al., 2008</xref>; <xref rid="B3" ref-type="bibr">Belzeaux et al., 2010</xref>; <xref rid="B43" ref-type="bibr">Rollins et al., 2010</xref>; <xref rid="B42" ref-type="bibr">Rivera-Baltanas et al., 2014</xref>; <xref rid="B9" ref-type="bibr">Cattane et al., 2015</xref>). The <italic>EGR</italic> and <italic>HTR2A</italic> genes are expressed in peripheral blood cells (<xref rid="B45" ref-type="bibr">Stefulj et al., 2000</xref>; <xref rid="B16" ref-type="bibr">Fukuda et al., 2006</xref>; <xref rid="B25" ref-type="bibr">Inoue et al., 2011</xref>; <xref rid="B9" ref-type="bibr">Cattane et al., 2015</xref>). The peripheral mRNA expression of several genes including the <italic>HTR2A</italic> gene were shown to have relatively similar expression profiles as in brain tissues (<xref rid="B17" ref-type="bibr">Glatt et al., 2005</xref>; <xref rid="B16" ref-type="bibr">Fukuda et al., 2006</xref>; <xref rid="B48" ref-type="bibr">Sullivan et al., 2006</xref>; <xref rid="B11" ref-type="bibr">Desjardins et al., 2008</xref>; <xref rid="B43" ref-type="bibr">Rollins et al., 2010</xref>; <xref rid="B53" ref-type="bibr">Yubero-Lahoz et al., 2015</xref>; <xref rid="B23" ref-type="bibr">GTExPortal, 2017</xref>). In healthy humans, <italic>HTR2A</italic> gene expression levels in whole blood correlated with 5-HT metabolite levels in the cerebrospinal fluid (<xref rid="B30" ref-type="bibr">Luykx et al., 2016</xref>). Peripheral <italic>EGR1</italic> expression was increased in patients with schizophrenia compared with healthy controls (<xref rid="B9" ref-type="bibr">Cattane et al., 2015</xref>).</p><p>Therefore, we expected altered <italic>HTR2A</italic> expression in response to LSD. Additionally, we hypothesized that LSD acutely increases <italic>EGR1</italic> and <italic>EGR2</italic> gene expression in humans similarly to rodents.</p></sec><sec sec-type="materials|methods" id="s1"><title>Materials and Methods</title><sec><title>Study Design</title><p>The study used a double-blind, placebo-controlled, cross-over design with two experimental test sessions in balanced order. The washout periods between sessions were at least 7 days. The study was conducted in accordance with the Declaration of Helsinki and International Conference on Harmonization Guidelines in Good Clinical Practice (ICH-GCP) and approved by the Ethics Committee of Northwestern Switzerland. The administration of LSD in healthy subjects was authorized by the Swiss Federal Office for Public Health, Bern, Switzerland. All of the subjects provided written informed consent and were paid for their participation. The study was registered at ClinicalTrials.gov (NCT02308969).</p></sec><sec><title>Participants</title><p>Twenty-four healthy subjects (12 men, 12 women; mean age &#x000b1; SD: 33 &#x000b1; 11 years; range: 25&#x02013;60 years) participated in the study. Blood samples for gene expression measurements were taken from only 15 participants (7 men, 8 women; mean age &#x000b1; SD: 28.5 &#x000b1; 5.8 years; range: 25&#x02013;48 years; mean weight &#x000b1; SD: 68 &#x000b1; 8 kg; range: 55&#x02013;85 kg; mean BMI &#x000b1; SD: 22.0 &#x000b1; 2.0 kg/m<sup>2</sup>; range: 19&#x02013;24 kg/m<sup>2</sup>). The inclusion and exclusion criteria, subjective, autonomic, and adverse effects of LSD, and pharmacokinetic data from this study have been reported in detail elsewhere (<xref rid="B14" ref-type="bibr">Dolder et al., 2016</xref>, <xref rid="B15" ref-type="bibr">2017</xref>; <xref rid="B29" ref-type="bibr">Liechti et al., 2017</xref>). Briefly, the participants had to be 25- to 65-years old and physically and mentally healthy. Additional exclusion criteria were pregnancy, tobacco smoking (&#x0003e;10 cigarettes/day), life-time prevalence of illicit drug use &#x0003e;10 times (except tetrahydrocannabinol), and illicit drug use within the past 2 months or during the study (determined by urine drug tests). Of the 15 subjects, only two had used a hallucinogen (LSD and psilocybin) once in their lives.</p></sec><sec><title>Study Procedures</title><p>The experimental sessions were conducted in a standard hospital patient room. The participants were resting in hospital beds except when going to the restroom. Only one research participant and one or two investigators were present during the experimental sessions. The participants could interact with the investigator, rest quietly, and/or listen to music via headphones, but no other entertainment was provided. LSD or placebo was administered at 9:00 AM. A standardized lunch and dinner were served at 1:30 and 5.30 PM, respectively. The subjects were never alone during the first 12 h after drug administration, and the investigator was in a room next to the subject for up to 24 h while the subject was asleep (mostly from 1:00 to 8:00 AM).</p></sec><sec><title>Study Drug</title><p>LSD (D-LSD, Lipomed AG, Arlesheim, Switzerland) was administered in a single oral dose of 100 &#x003bc;g as a capsule. The dose was within the range of doses that are taken for recreational purposes (<xref rid="B38" ref-type="bibr">Passie et al., 2008</xref>; <xref rid="B37" ref-type="bibr">Nichols, 2016</xref>). Corresponding placebo capsules were used.</p></sec><sec><title>Measures</title><sec><title>Gene Expression</title><p>Blood samples were collected before and 1.5 and 24 h after drug administration using the PAXgene<sup>TM</sup> Blood RNA system (Becton Dickinson, Heidelberg, Germany). The 1.5 h time point was selected to coincide with the peak of the plasma concentration of LSD (<xref rid="B13" ref-type="bibr">Dolder et al., 2015b</xref>). The 24 h time point was selected because partial tolerance by that time has been documented (<xref rid="B10" ref-type="bibr">Cholden et al., 1955</xref>; <xref rid="B1" ref-type="bibr">Abramson et al., 1956</xref>; <xref rid="B2" ref-type="bibr">Belleville et al., 1956</xref>). Samples were incubated for 2 h at room temperature, followed by freezing at -80&#x000b0;C until further processing. Total RNA was prepared using the PAXgene<sup>TM</sup> Blood RNA Kit 50 (PreAnalytiX, Qiagen, Hilden, Germany). Total RNA samples were spectrophotometrically scanned (260 and 280 nm; NanoVue, GE Healthcare Life Sciences, Glattbrugg, Switzerland). A260 was used for RNA quantification. The A260/A280 ratio was &#x0003e;1.9, excluding relevant protein contamination. RNA quality was also measured using Experion RNA chips (BioRad, Hercules, CA, United States) providing the RNA quality indicator (RQI &#x0003e; 7). Quantitative real-time polymerase chain reaction (PCR) was performed for the <italic>HTR2A</italic>, <italic>EGR1</italic>, <italic>EGR2</italic>, and <italic>EGR3</italic> genes and six additional reference genes (<italic>ACTB</italic>, <italic>GAPDH</italic>, <italic>ALAS1</italic>, <italic>RPL13A</italic>, <italic>PPIA</italic>, and <italic>RRN18S</italic>) as described previously (<xref rid="B22" ref-type="bibr">Grunblatt et al., 2009</xref>). The investigated genes are listed in detail in <bold>Table <xref ref-type="table" rid="T1">1</xref></bold>. Total RNA (500 ng) from each sample was reverse-transcribed using the iScript cDNA synthesis kit (BioRad, Hercules, CA, United States). Each amplification was performed in a total volume of 10 &#x003bc;l that contained 5 &#x003bc;l of the QuantiFast SYBR Green PCR kit (Qiagen, Hilden, Germany) and the specific PrimerAssay (Qiagen, Hilden, Germany). The PCR conditions were run on a CFX384 device (BioRad, Hercules, CA, United States) according to manufacturer&#x02019;s manual, with the exception of <italic>HTR2A</italic> primers, in which annealing occurred at 56&#x000b0;C according to a gradient analysis (Qiagen, Hilden, Germany). A melting-point analysis was conducted for each assay to confirm the specificity of the PCR products. All of the PCR reactions were run in triplicate. LinRegPCR 2016.0 software (Hart Failure Research Center, Amsterdam, The Netherlands; <xref rid="B40" ref-type="bibr">Ramakers et al., 2003</xref>) was used to determine the PCR efficiency. The analysis of gene expression and normalization with the most stable reference genes was conducted using qBasePlus 3.0 software (Biogazelle, Gent, The Netherlands; <xref rid="B50" ref-type="bibr">Vandesompele et al., 2002</xref>). Since the consensus is that there are no real reference (housekeeping) genes, there is a need to use more than one reference genes as well as test them before normalization is conducted (<xref rid="B50" ref-type="bibr">Vandesompele et al., 2002</xref>). The reference genes <italic>GAPDH</italic> and <italic>PPIA</italic> were the least stable and thus excluded, and the normalization analysis was conducted using the four remaining reference genes (<italic>ACTB</italic>, <italic>ALAS1</italic>, <italic>RPL13A</italic>, and <italic>RRN18S</italic>).</p><table-wrap id="T1" position="float"><label>Table 1</label><caption><p>List of investigated genes.</p></caption><table frame="hsides" rules="groups" cellspacing="5" cellpadding="5"><thead><tr><th valign="top" align="left" rowspan="1" colspan="1">Gene name</th><th valign="top" align="left" rowspan="1" colspan="1">Abbreviation</th><th valign="top" align="left" rowspan="1" colspan="1">Qiagen (cat. no.)</th><th valign="top" align="left" rowspan="1" colspan="1">Gene bank accession no.</th></tr></thead><tbody><tr><td valign="top" align="left" colspan="4" rowspan="1"><bold>Reference genes</bold></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x003b2;-Actin</td><td valign="top" align="left" rowspan="1" colspan="1">ACTB<sup>&#x02217;</sup></td><td valign="top" align="left" rowspan="1" colspan="1">QT00095431</td><td valign="top" align="left" rowspan="1" colspan="1">NM_001101</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Glyceraldehydes-3-phosphate dehydrogenase</td><td valign="top" align="left" rowspan="1" colspan="1">GAPDH</td><td valign="top" align="left" rowspan="1" colspan="1">QT00079247</td><td valign="top" align="left" rowspan="1" colspan="1">NM_002046</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Aminolevulinate delta synthase 1</td><td valign="top" align="left" rowspan="1" colspan="1">ALAS1<sup>&#x02217;</sup></td><td valign="top" align="left" rowspan="1" colspan="1">QT00073122</td><td valign="top" align="left" rowspan="1" colspan="1">NM_000688</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Ribosomal protein L13a</td><td valign="top" align="left" rowspan="1" colspan="1">RPL13A<sup>&#x02217;</sup></td><td valign="top" align="left" rowspan="1" colspan="1">QT00089915</td><td valign="top" align="left" rowspan="1" colspan="1">NM_012423</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Peptidylprolyl isomerase A</td><td valign="top" align="left" rowspan="1" colspan="1">PPIA</td><td valign="top" align="left" rowspan="1" colspan="1">QT00052311</td><td valign="top" align="left" rowspan="1" colspan="1">NM_021130</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">18s ribosomal</td><td valign="top" align="left" rowspan="1" colspan="1">RRN18S<sup>&#x02217;</sup></td><td valign="top" align="left" rowspan="1" colspan="1">QT00199367</td><td valign="top" align="left" rowspan="1" colspan="1">V01270</td></tr><tr><td valign="top" align="left" colspan="4" rowspan="1"><bold>Genes of interest</bold></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Serotonin 2a receptor</td><td valign="top" align="left" rowspan="1" colspan="1">HTR2A</td><td valign="top" align="left" rowspan="1" colspan="1">QT00054306</td><td valign="top" align="left" rowspan="1" colspan="1">NM_000621</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Early growth response 1</td><td valign="top" align="left" rowspan="1" colspan="1">EGR1</td><td valign="top" align="left" rowspan="1" colspan="1">QT00218505</td><td valign="top" align="left" rowspan="1" colspan="1">NM_001964</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Early growth response 2</td><td valign="top" align="left" rowspan="1" colspan="1">EGR2</td><td valign="top" align="left" rowspan="1" colspan="1">QT00000924</td><td valign="top" align="left" rowspan="1" colspan="1">NM_000399</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Early growth response 3</td><td valign="top" align="left" rowspan="1" colspan="1">EGR3</td><td valign="top" align="left" rowspan="1" colspan="1">QT00246498</td><td valign="top" align="left" rowspan="1" colspan="1">NM_001199880</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">NM_001199881 NM_004430</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"/></tr></tbody></table><table-wrap-foot><attrib><italic><sup>&#x02217;</sup>Most stable reference genes used for normalization.</italic></attrib></table-wrap-foot></table-wrap></sec><sec><title>Plasma Concentrations of LSD</title><p>Blood was collected in lithium heparin tubes before and 1, 2, 3, 4, 6, 8, 10, 12, 16, and 24 h after LSD administration. The blood samples were immediately centrifuged, and the plasma was rapidly stored at -20&#x000b0;C and later at -80&#x000b0;C until analysis. LSD concentrations in plasma were determined using liquid-chromatography-tandem mass-spectrometry as reported in detail elsewhere (<xref rid="B12" ref-type="bibr">Dolder et al., 2015a</xref>; <xref rid="B46" ref-type="bibr">Steuer et al., 2016</xref>). The lower limit of quantification was 0.05 ng/ml (<xref rid="B12" ref-type="bibr">Dolder et al., 2015a</xref>). The pharmacokinetics of LSD from the present study are presented in detail elsewhere (<xref rid="B15" ref-type="bibr">Dolder et al., 2017</xref>).</p></sec></sec><sec><title>Statistics</title><p>The statistical analyses were performed using Statistica 12 software (StatSoft, Tulsa, OK, United States). Baseline gene expression values before drug administration were set to 1, and changes after 1.5 and 24 h are expressed as fold changes from baseline. Differences between LSD and placebo at the corresponding time points were then analyzed using paired <italic>t</italic>-tests. All comparisons were also made with data standardized to the mean age, body weight, and peak plasma concentrations of LSD. The criterion for significance was <italic>p</italic> &#x0003c; 0.05 without correction for multiple comparisons. Additionally, to test for changes in gene expression over time after administration of LSD or placebo, repeated measures analyses of variance (ANOVAs) were conducted with time (0, 1.5, and 24 h) as within-subject factor followed by Tukey <italic>post hoc</italic> test. To assess potential moderating effects by sex, sex was added as additional between-subjects factor to the ANOVAs.</p></sec></sec><sec><title>Results</title><p>Three samples after 24 h had insufficient amounts of RNA to be included in the analysis (<bold>Table <xref ref-type="table" rid="T2">2</xref></bold>). The expression patterns of the <italic>HTR2A</italic>, <italic>EGR1</italic>, <italic>EGR2</italic>, and <italic>EGR3</italic> genes were unchanged 1.5 and 24 h after the administration of LSD compared with placebo (<bold>Figure <xref ref-type="fig" rid="F1">1</xref></bold> and <bold>Table <xref ref-type="table" rid="T2">2</xref></bold>). Expression did also not change over time after LSD and placebo (HTR2A: <italic>F</italic><sub>2,24</sub> = 0.02, <italic>P</italic> = 1.0 and <italic>F</italic><sub>2,26</sub> = 1.24, <italic>P</italic> = 0.3; EGR1: <italic>F</italic><sub>2,24</sub> = 1.14, <italic>P</italic> = 0.3 and <italic>F</italic><sub>2,26</sub> = 1.9, <italic>P</italic> = 0.2; EGR2: <italic>F</italic><sub>2,24</sub> = 1.20, <italic>P</italic> = 0.3 and <italic>F</italic><sub>2,26</sub> = 2.67, <italic>P</italic> = 0.09; EGR3: <italic>F</italic><sub>2,24</sub> = 1.17, <italic>P</italic> = 0.2 and <italic>F</italic><sub>2,24</sub> = 0.08, <italic>P</italic> = 0.9, respectively). Sex did not moderate the effects of LSD or placebo on gene expression. Additionally, the findings were similar if the data was standardized to the mean age, body weight or plasma concentration of LSD.</p><table-wrap id="T2" position="float"><label>Table 2</label><caption><p>Lysergic acid diethylamide-induced changes in gene expression.</p></caption><table frame="hsides" rules="groups" cellspacing="5" cellpadding="5"><thead><tr><th valign="top" align="left" rowspan="1" colspan="1">Gene</th><th valign="top" align="center" rowspan="1" colspan="1">Time after LSD</th><th valign="top" align="center" rowspan="1" colspan="1"><italic>n</italic></th><th valign="top" align="center" rowspan="1" colspan="1">LSD vs. placebo<sup>a</sup></th><th valign="top" align="center" rowspan="1" colspan="1"><italic>p</italic>-value<sup>b</sup></th></tr></thead><tbody><tr><td valign="top" align="left" rowspan="1" colspan="1"><italic>HTR2A</italic></td><td valign="top" align="center" rowspan="1" colspan="1">1.5 h</td><td valign="top" align="center" rowspan="1" colspan="1">15</td><td valign="top" align="center" rowspan="1" colspan="1">0.51 (0.13)</td><td valign="top" align="center" rowspan="1" colspan="1">0.39</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">24 h</td><td valign="top" align="center" rowspan="1" colspan="1">12</td><td valign="top" align="center" rowspan="1" colspan="1">0.07 (0.02)</td><td valign="top" align="center" rowspan="1" colspan="1">0.90</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><italic>EGR1</italic></td><td valign="top" align="center" rowspan="1" colspan="1">1.5 h</td><td valign="top" align="center" rowspan="1" colspan="1">15</td><td valign="top" align="center" rowspan="1" colspan="1">-0.1 (-0.03)</td><td valign="top" align="center" rowspan="1" colspan="1">0.83</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">24 h</td><td valign="top" align="center" rowspan="1" colspan="1">12</td><td valign="top" align="center" rowspan="1" colspan="1">0.47 (0.14)</td><td valign="top" align="center" rowspan="1" colspan="1">0.10</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><italic>EGR2</italic></td><td valign="top" align="center" rowspan="1" colspan="1">1.5 h</td><td valign="top" align="center" rowspan="1" colspan="1">15</td><td valign="top" align="center" rowspan="1" colspan="1">0.04 (0.01)</td><td valign="top" align="center" rowspan="1" colspan="1">0.86</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">24 h</td><td valign="top" align="center" rowspan="1" colspan="1">12</td><td valign="top" align="center" rowspan="1" colspan="1">0.27 (0.08)</td><td valign="top" align="center" rowspan="1" colspan="1">0.22</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><italic>EGR3</italic></td><td valign="top" align="center" rowspan="1" colspan="1">1.5 h</td><td valign="top" align="center" rowspan="1" colspan="1">15</td><td valign="top" align="center" rowspan="1" colspan="1">0.20 (0.05)</td><td valign="top" align="center" rowspan="1" colspan="1">0.24</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">24 h</td><td valign="top" align="center" rowspan="1" colspan="1">11</td><td valign="top" align="center" rowspan="1" colspan="1">0.40 (0.12)</td><td valign="top" align="center" rowspan="1" colspan="1">0.16</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"/></tr></tbody></table><table-wrap-foot><attrib><italic><italic>HTR2A</italic>, serotonin 2a receptor gene; <italic>EGR</italic>, early growth response gene; n, number of samples. <sup>a</sup>Gene expression values are differences (mean and [SEM]) between LSD and placebo at the respective time point for fold-changes from baseline; <sup>b</sup><italic>t</italic>-tests.</italic></attrib></table-wrap-foot></table-wrap><fig id="F1" position="float"><label>FIGURE 1</label><caption><p>Lysergic acid diethylamide did not alter gene expression. The levels of expression of the 5-HT<sub>2A</sub> receptor gene (<italic>HTR2A</italic>) and early growth response genes (<italic>EGR1</italic>, <italic>EGR2</italic>, and <italic>EGR3</italic>) were determined before and 1.5 and 24 h after administration of 100 &#x003bc;g LSD or placebo. The data are expressed as the mean &#x000b1; SEM of mRNA expression levels relative to reference genes with stable expression. The respective differences in fold-changes from baseline are show in <bold>Table <xref ref-type="table" rid="T2">2</xref></bold>.</p></caption><graphic xlink:href="fphar-08-00423-g001"/></fig></sec><sec><title>Discussion</title><p>The key finding of the present study was that acute LSD administration did not alter the expression of the <italic>HTR2A</italic> and <italic>EGR1-3</italic> genes in humans using peripheral blood cells as peripheral biomarker possibly reflecting central gene expression. The lack of an acute effect of LSD on <italic>HTR2A</italic> gene expression in humans is consistent with a study in rats that reported no changes in <italic>HTR2A</italic> gene expression in different brain areas (<xref rid="B35" ref-type="bibr">Nichols and Sanders-Bush, 2002</xref>). However, 5-HT<sub>2A</sub> receptor availability may also be altered independently of <italic>HTR2A</italic> gene expression (e.g., by receptor internalization or moderation of its activity). Several studies in rats (<xref rid="B5" ref-type="bibr">Buckholtz et al., 1985</xref>, <xref rid="B6" ref-type="bibr">1990</xref>; <xref rid="B21" ref-type="bibr">Gresch et al., 2005</xref>; <xref rid="B4" ref-type="bibr">Buchborn et al., 2015</xref>) reported a decrease in 5-HT<sub>2A</sub> receptor binding in the prefrontal cortex or consistent trend effects (<xref rid="B4" ref-type="bibr">Buchborn et al., 2015</xref>) after repeated LSD administration. Unknown, however, is whether lower binding also occurs after single-dose administration. The present findings of no changes in <italic>EGR1</italic> and <italic>EGR2</italic> gene expression in human blood samples after acute LSD administration contrast with preclinical findings. Specifically, LSD rapidly increased <italic>EGR1</italic> and <italic>EGR2</italic> expression in the cortex in rats (<xref rid="B35" ref-type="bibr">Nichols and Sanders-Bush, 2002</xref>, <xref rid="B36" ref-type="bibr">2004</xref>; <xref rid="B34" ref-type="bibr">Nichols et al., 2003</xref>) and mice (<xref rid="B20" ref-type="bibr">Gonzalez-Maeso et al., 2003</xref>, <xref rid="B19" ref-type="bibr">2007</xref>). We expected similar rapid increases in <italic>EGR1</italic> and <italic>EGR2</italic> expression in humans. Importantly, however, we evaluated gene expression in human blood samples, whereas the animal studies evaluated gene expression in brain tissue. Thus, it is possible that LSD alters gene expression in the brain and not in blood.</p><p>Tolerance to repeated LSD administration reportedly begins with the second daily dose of LSD, and complete tolerance develops within 3&#x02013;4 days of repeated LSD administration in humans according to older studies (<xref rid="B10" ref-type="bibr">Cholden et al., 1955</xref>; <xref rid="B1" ref-type="bibr">Abramson et al., 1956</xref>; <xref rid="B2" ref-type="bibr">Belleville et al., 1956</xref>; <xref rid="B38" ref-type="bibr">Passie et al., 2008</xref>; <xref rid="B37" ref-type="bibr">Nichols, 2016</xref>) that need to be replicated. In the present study, we found no evidence of acute pharmacological tolerance within 12 h of acute LSD administration at a dose of 100 &#x003bc;g as documented in detail elsewhere (<xref rid="B15" ref-type="bibr">Dolder et al., 2017</xref>). Similarly, no acute tolerance was observed after single-dose administration of 200 &#x003bc;g LSD in humans within 24 h (<xref rid="B13" ref-type="bibr">Dolder et al., 2015b</xref>, <xref rid="B15" ref-type="bibr">2017</xref>). Thus, after one dose of LSD, subjective effects of LSD were self-reported by the participants as long as LSD was present in plasma, and the subjective effects did not decline more rapidly than the plasma concentrations of LSD (<xref rid="B15" ref-type="bibr">Dolder et al., 2017</xref>). This is consistent with the view that LSD directly activates 5-HT<sub>2A</sub> receptors to produce its mind-altering effects as long as it is present in the effect compartment (i.e., the brain) and assuming largely similar plasma and effect compartment kinetics. The finding of no acute tolerance in the participants in the present study (<xref rid="B15" ref-type="bibr">Dolder et al., 2017</xref>) also indicates that no relevant counterregulatory neuroadaptations occurred or were evident with the first 12&#x02013;24 h after LSD administration. A recent study showed that LSD dissociates very slowly from the 5-HT<sub>2A</sub> receptor, and the authors proposed that the high potency and long effect duration of LSD could be linked to a unique receptor interaction (<xref rid="B52" ref-type="bibr">Wacker et al., 2017</xref>). However, the LSD concentration-effect relationship (<xref rid="B15" ref-type="bibr">Dolder et al., 2017</xref>) shows that the presence of LSD in the body sufficiently accounted for the duration of its subjective effects. Doubling the LSD dose resulted in prolongation of the effect by approximately 3 h, consistent with its half-life of approximately 3 h (<xref rid="B15" ref-type="bibr">Dolder et al., 2017</xref>). In contrast to the pharmacokinetic&#x02013;pharmacodynamic relationship of LSD (<xref rid="B15" ref-type="bibr">Dolder et al., 2017</xref>), other psychoactive substances, such as 3,4-methylenedioxymethamphetamine (MDMA), exhibit very marked acute pharmacological tolerance, with a rapid decline of subjective and physiological effects of MDMA within 4 h despite continuously high plasma levels and a relatively long half-life of 8 h (<xref rid="B24" ref-type="bibr">Hysek et al., 2010</xref>; <xref rid="B51" ref-type="bibr">Vizeli and Liechti, 2017</xref>).</p></sec><sec><title>Limitations</title><p>The present study has several limitations. First, we assessed the effects of only an acute single dose of LSD on gene expression and tolerance. Further repeated dose administration studies need to be conducted. Second, we used only a moderate single dose of LSD, and the study sample was relatively small. Third, we assessed gene expression only at 1.5 and 24 h after LSD administration. Therefore, we may have missed effects that may have occurred between these time points. In fact, increases in <italic>EGR2</italic> were observed only up to 5 h in rats (<xref rid="B35" ref-type="bibr">Nichols and Sanders-Bush, 2002</xref>; <xref rid="B20" ref-type="bibr">Gonzalez-Maeso et al., 2003</xref>; <xref rid="B34" ref-type="bibr">Nichols et al., 2003</xref>). Fourth, all changes in gene expression that are caused by LSD that have been reported to date have been observed animal brains, whereas our study focused solely on human blood cells as a peripheral biomarker of the central nervous system (<xref rid="B48" ref-type="bibr">Sullivan et al., 2006</xref>; <xref rid="B32" ref-type="bibr">Mohr and Liew, 2007</xref>; <xref rid="B11" ref-type="bibr">Desjardins et al., 2008</xref>; <xref rid="B3" ref-type="bibr">Belzeaux et al., 2010</xref>; <xref rid="B43" ref-type="bibr">Rollins et al., 2010</xref>; <xref rid="B42" ref-type="bibr">Rivera-Baltanas et al., 2014</xref>; <xref rid="B9" ref-type="bibr">Cattane et al., 2015</xref>).</p></sec><sec><title>Conclusion</title><p>In summary, an acute single dose of LSD in humans did not acutely alter the expression of the <italic>HTR2A</italic> and <italic>EGR1-3</italic> genes in peripheral mononuclear blood cells and thus did not influence potential markers of neuroadaptation.</p></sec><sec><title>Author Contributions</title><p>Each of the authors participated in this research by contributing to the conception and design of the study (PD and ML), study management (PD, FM, and SB) performance of laboratory experiments (EG) and statistical analysis and interpretation (PD, EG, and ML).</p></sec><sec><title>Conflict of Interest Statement</title><p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p></sec></body><back><fn-group><fn fn-type="financial-disclosure"><p><bold>Funding.</bold> This work was supported by the Swiss National Science Foundation (grant no. 320030_170249 to ML and SB) and the University of Basel (to FM).</p></fn></fn-group><ack><p>The authors thank Miryame Hofmann, Susanne Kunert-D&#x000fc;mpelmann, and Sonja Fetz for technical assistance and Michael Arends for text editing.</p></ack><ref-list><title>References</title><ref id="B1"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Abramson</surname><given-names>H. A.</given-names></name><name><surname>Jarvik</surname><given-names>M. E.</given-names></name><name><surname>Gorin</surname><given-names>M. H.</given-names></name><name><surname>Hirsch</surname><given-names>M. W.</given-names></name></person-group> (<year>1956</year>). <article-title>Lysergic acid diethylamide (LSD-25): XVII. Tolerance development and its relationship to a theory of psychosis.</article-title>
<source><italic>J. Psychol.</italic></source>
<volume>41</volume>
<fpage>81</fpage>&#x02013;<lpage>105</lpage>. <pub-id pub-id-type="doi">10.1080/00223980.1956.9916206</pub-id></mixed-citation></ref><ref id="B2"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Belleville</surname><given-names>R. E.</given-names></name><name><surname>Fraser</surname><given-names>H. F.</given-names></name><name><surname>Isbell</surname><given-names>H.</given-names></name><name><surname>Wikler</surname><given-names>A.</given-names></name><name><surname>Logan</surname><given-names>C. R.</given-names></name></person-group> (<year>1956</year>). <article-title>Studies on lysergic acid diethylamide (LSD-25): I. Effects in former morphine addicts and development of tolerance during chronic intoxication.</article-title>
<source><italic>AMA Arch. Neurol. Psychiatry</italic></source>
<volume>76</volume>
<fpage>468</fpage>&#x02013;<lpage>478</lpage>. <pub-id pub-id-type="doi">10.1001/archneurpsyc.1956.02330290012002</pub-id><pub-id pub-id-type="pmid">13371962</pub-id></mixed-citation></ref><ref id="B3"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Belzeaux</surname><given-names>R.</given-names></name><name><surname>Formisano-Treziny</surname><given-names>C.</given-names></name><name><surname>Loundou</surname><given-names>A.</given-names></name><name><surname>Boyer</surname><given-names>L.</given-names></name><name><surname>Gabert</surname><given-names>J.</given-names></name><name><surname>Samuelian</surname><given-names>J. C.</given-names></name><etal/></person-group> (<year>2010</year>). <article-title>Clinical variations modulate patterns of gene expression and define blood biomarkers in major depression.</article-title>
<source><italic>J. Psychiatr. Res.</italic></source>
<volume>44</volume>
<fpage>1205</fpage>&#x02013;<lpage>1213</lpage>. <pub-id pub-id-type="doi">10.1016/j.jpsychires.2010.04.011</pub-id><pub-id pub-id-type="pmid">20471034</pub-id></mixed-citation></ref><ref id="B4"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Buchborn</surname><given-names>T.</given-names></name><name><surname>Schroder</surname><given-names>H.</given-names></name><name><surname>Dieterich</surname><given-names>D. C.</given-names></name><name><surname>Grecksch</surname><given-names>G.</given-names></name><name><surname>Hollt</surname><given-names>V.</given-names></name></person-group> (<year>2015</year>). <article-title>Tolerance to LSD and DOB induced shaking behaviour: differential adaptations of frontocortical 5-HT2A and glutamate receptor binding sites.</article-title>
<source><italic>Behav. Brain Res.</italic></source>
<volume>281</volume>
<fpage>62</fpage>&#x02013;<lpage>68</lpage>. <pub-id pub-id-type="doi">10.1016/j.bbr.2014.12.014</pub-id><pub-id pub-id-type="pmid">25513973</pub-id></mixed-citation></ref><ref id="B5"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Buckholtz</surname><given-names>N. S.</given-names></name><name><surname>Freedman</surname><given-names>D. X.</given-names></name><name><surname>Middaugh</surname><given-names>L. D.</given-names></name></person-group> (<year>1985</year>). <article-title>Daily LSD administration selectively decreases serotonin2 receptor binding in rat brain.</article-title>
<source><italic>Eur. J. Pharmacol.</italic></source>
<volume>109</volume>
<fpage>421</fpage>&#x02013;<lpage>425</lpage>. <pub-id pub-id-type="doi">10.1016/0014-2999(85)90407-8</pub-id><pub-id pub-id-type="pmid">3987809</pub-id></mixed-citation></ref><ref id="B6"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Buckholtz</surname><given-names>N. S.</given-names></name><name><surname>Zhou</surname><given-names>D. F.</given-names></name><name><surname>Freedman</surname><given-names>D. X.</given-names></name><name><surname>Potter</surname><given-names>W. Z.</given-names></name></person-group> (<year>1990</year>). <article-title>Lysergic acid diethylamide (LSD) administration selectively downregulates serotonin2 receptors in rat brain.</article-title>
<source><italic>Neuropsychopharmacology</italic></source>
<volume>3</volume>
<fpage>137</fpage>&#x02013;<lpage>148</lpage>.<pub-id pub-id-type="pmid">1969270</pub-id></mixed-citation></ref><ref id="B7"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Carhart-Harris</surname><given-names>R. L.</given-names></name><name><surname>Kaelen</surname><given-names>M.</given-names></name><name><surname>Bolstridge</surname><given-names>M.</given-names></name><name><surname>Williams</surname><given-names>T. M.</given-names></name><name><surname>Williams</surname><given-names>L. T.</given-names></name><name><surname>Underwood</surname><given-names>R.</given-names></name><etal/></person-group> (<year>2016a</year>). <article-title>The paradoxical psychological effects of lysergic acid diethylamide (LSD).</article-title>
<source><italic>Psychol. Med.</italic></source>
<volume>46</volume>
<fpage>1379</fpage>&#x02013;<lpage>1390</lpage>. <pub-id pub-id-type="doi">10.1017/S0033291715002901</pub-id><pub-id pub-id-type="pmid">26847689</pub-id></mixed-citation></ref><ref id="B8"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Carhart-Harris</surname><given-names>R. L.</given-names></name><name><surname>Muthukumaraswamy</surname><given-names>S.</given-names></name><name><surname>Roseman</surname><given-names>L.</given-names></name><name><surname>Kaelen</surname><given-names>M.</given-names></name><name><surname>Droog</surname><given-names>W.</given-names></name><name><surname>Murphy</surname><given-names>K.</given-names></name><etal/></person-group> (<year>2016b</year>). <article-title>Neural correlates of the LSD experience revealed by multimodal neuroimaging.</article-title>
<source><italic>Proc. Natl. Acad. Sci. U.S.A.</italic></source>
<volume>113</volume>
<fpage>4853</fpage>&#x02013;<lpage>4858</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.1518377113</pub-id><pub-id pub-id-type="pmid">27071089</pub-id></mixed-citation></ref><ref id="B9"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cattane</surname><given-names>N.</given-names></name><name><surname>Minelli</surname><given-names>A.</given-names></name><name><surname>Milanesi</surname><given-names>E.</given-names></name><name><surname>Maj</surname><given-names>C.</given-names></name><name><surname>Bignotti</surname><given-names>S.</given-names></name><name><surname>Bortolomasi</surname><given-names>M.</given-names></name><etal/></person-group> (<year>2015</year>). <article-title>Altered gene expression in schizophrenia: findings from transcriptional signatures in fibroblasts and blood.</article-title>
<source><italic>PLoS ONE</italic></source>
<volume>10</volume>:<issue>e0116686</issue>
<pub-id pub-id-type="doi">10.1371/journal.pone.0116686</pub-id></mixed-citation></ref><ref id="B10"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cholden</surname><given-names>L. S.</given-names></name><name><surname>Kurland</surname><given-names>A.</given-names></name><name><surname>Savage</surname><given-names>C.</given-names></name></person-group> (<year>1955</year>). <article-title>Clinical reactions and tolerance to LSD in chronic schizophrenia.</article-title>
<source><italic>J. Nerv. Ment. Dis.</italic></source>
<volume>122</volume>
<fpage>211</fpage>&#x02013;<lpage>221</lpage>. <pub-id pub-id-type="doi">10.1097/00005053-195509000-00001</pub-id><pub-id pub-id-type="pmid">13295823</pub-id></mixed-citation></ref><ref id="B11"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Desjardins</surname><given-names>S.</given-names></name><name><surname>Belkai</surname><given-names>E.</given-names></name><name><surname>Crete</surname><given-names>D.</given-names></name><name><surname>Cordonnier</surname><given-names>L.</given-names></name><name><surname>Scherrmann</surname><given-names>J. M.</given-names></name><name><surname>Noble</surname><given-names>F.</given-names></name><etal/></person-group> (<year>2008</year>). <article-title>Effects of chronic morphine and morphine withdrawal on gene expression in rat peripheral blood mononuclear cells.</article-title>
<source><italic>Neuropharmacology</italic></source>
<volume>55</volume>
<fpage>1347</fpage>&#x02013;<lpage>1354</lpage>. <pub-id pub-id-type="doi">10.1016/j.neuropharm.2008.08.027</pub-id><pub-id pub-id-type="pmid">18801381</pub-id></mixed-citation></ref><ref id="B12"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dolder</surname><given-names>P. C.</given-names></name><name><surname>Liechti</surname><given-names>M. E.</given-names></name><name><surname>Rentsch</surname><given-names>K. M.</given-names></name></person-group> (<year>2015a</year>). <article-title>Development and validation of a rapid turboflow LC-MS/MS method for the quantification of LSD and 2-oxo-3-hydroxy LSD in serum and urine samples of emergency toxicological cases.</article-title>
<source><italic>Anal. Bioanal. Chem.</italic></source>
<volume>407</volume>
<fpage>1577</fpage>&#x02013;<lpage>1584</lpage>. <pub-id pub-id-type="doi">10.1007/s00216-014-8388-1</pub-id><pub-id pub-id-type="pmid">25542574</pub-id></mixed-citation></ref><ref id="B13"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dolder</surname><given-names>P. C.</given-names></name><name><surname>Schmid</surname><given-names>Y.</given-names></name><name><surname>Haschke</surname><given-names>M.</given-names></name><name><surname>Rentsch</surname><given-names>K. M.</given-names></name><name><surname>Liechti</surname><given-names>M. E.</given-names></name></person-group> (<year>2015b</year>). <article-title>Pharmacokinetics and concentration-effect relationship of oral LSD in humans.</article-title>
<source><italic>Int. J. Neuropsychopharmacol.</italic></source>
<volume>19</volume>:<issue>pyv072</issue>
<pub-id pub-id-type="doi">10.1093/ijnp/pyv072</pub-id></mixed-citation></ref><ref id="B14"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dolder</surname><given-names>P. C.</given-names></name><name><surname>Schmid</surname><given-names>Y.</given-names></name><name><surname>Mueller</surname><given-names>F.</given-names></name><name><surname>Borgwardt</surname><given-names>S.</given-names></name><name><surname>Liechti</surname><given-names>M. E.</given-names></name></person-group> (<year>2016</year>). <article-title>LSD acutely impairs fear recognition and enhances emotional empathy and sociality.</article-title>
<source><italic>Neuropsychopharmacology</italic></source>
<volume>41</volume>
<fpage>2638</fpage>&#x02013;<lpage>2646</lpage>. <pub-id pub-id-type="doi">10.1038/npp.2016.82</pub-id><pub-id pub-id-type="pmid">27249781</pub-id></mixed-citation></ref><ref id="B15"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dolder</surname><given-names>P. C.</given-names></name><name><surname>Schmid</surname><given-names>Y.</given-names></name><name><surname>Steuer</surname><given-names>A. E.</given-names></name><name><surname>Kraemer</surname><given-names>T.</given-names></name><name><surname>Rentsch</surname><given-names>K. M.</given-names></name><name><surname>Hammann</surname><given-names>F.</given-names></name><etal/></person-group> (<year>2017</year>). <article-title>Pharmacokinetics and pharmacodynamics of lysergic acid diethylamide in healthy subjects.</article-title>
<source><italic>Clin. Pharmacokinet.</italic></source>
<pub-id pub-id-type="doi">10.1007/s40262-017-0513-9</pub-id>
<comment>[Epub ahead of print]</comment>.</mixed-citation></ref><ref id="B16"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fukuda</surname><given-names>Y.</given-names></name><name><surname>Koga</surname><given-names>M.</given-names></name><name><surname>Arai</surname><given-names>M.</given-names></name><name><surname>Noguchi</surname><given-names>E.</given-names></name><name><surname>Ohtsuki</surname><given-names>T.</given-names></name><name><surname>Horiuchi</surname><given-names>Y.</given-names></name><etal/></person-group> (<year>2006</year>). <article-title>Monoallelic and unequal allelic expression of the HTR2A gene in human brain and peripheral lymphocytes.</article-title>
<source><italic>Biol. Psychiatry</italic></source>
<volume>60</volume>
<fpage>1331</fpage>&#x02013;<lpage>1335</lpage>. <pub-id pub-id-type="doi">10.1016/j.biopsych.2006.06.024</pub-id><pub-id pub-id-type="pmid">17069769</pub-id></mixed-citation></ref><ref id="B17"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Glatt</surname><given-names>S. J.</given-names></name><name><surname>Everall</surname><given-names>I. P.</given-names></name><name><surname>Kremen</surname><given-names>W. S.</given-names></name><name><surname>Corbeil</surname><given-names>J.</given-names></name><name><surname>Sasik</surname><given-names>R.</given-names></name><name><surname>Khanlou</surname><given-names>N.</given-names></name><etal/></person-group> (<year>2005</year>). <article-title>Comparative gene expression analysis of blood and brain provides concurrent validation of SELENBP1 up-regulation in schizophrenia.</article-title>
<source><italic>Proc. Natl. Acad. Sci. U.S.A.</italic></source>
<volume>102</volume>
<fpage>15533</fpage>&#x02013;<lpage>15538</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.0507666102</pub-id><pub-id pub-id-type="pmid">16223876</pub-id></mixed-citation></ref><ref id="B18"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gonzalez-Maeso</surname><given-names>J.</given-names></name><name><surname>Ang</surname><given-names>R. L.</given-names></name><name><surname>Yuen</surname><given-names>T.</given-names></name><name><surname>Chan</surname><given-names>P.</given-names></name><name><surname>Weisstaub</surname><given-names>N. V.</given-names></name><name><surname>Lopez-Gimenez</surname><given-names>J. F.</given-names></name><etal/></person-group> (<year>2008</year>). <article-title>Identification of a serotonin/glutamate receptor complex implicated in psychosis.</article-title>
<source><italic>Nature</italic></source>
<volume>452</volume>
<fpage>93</fpage>&#x02013;<lpage>97</lpage>. <pub-id pub-id-type="doi">10.1038/nature06612</pub-id><pub-id pub-id-type="pmid">18297054</pub-id></mixed-citation></ref><ref id="B19"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gonzalez-Maeso</surname><given-names>J.</given-names></name><name><surname>Weisstaub</surname><given-names>N. V.</given-names></name><name><surname>Zhou</surname><given-names>M.</given-names></name><name><surname>Chan</surname><given-names>P.</given-names></name><name><surname>Ivic</surname><given-names>L.</given-names></name><name><surname>Ang</surname><given-names>R.</given-names></name><etal/></person-group> (<year>2007</year>). <article-title>Hallucinogens recruit specific cortical 5-HT2A receptor-mediated signaling pathways to affect behavior.</article-title>
<source><italic>Neuron</italic></source>
<volume>53</volume>
<fpage>439</fpage>&#x02013;<lpage>452</lpage>. <pub-id pub-id-type="doi">10.1016/j.neuron.2007.01.008</pub-id><pub-id pub-id-type="pmid">17270739</pub-id></mixed-citation></ref><ref id="B20"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gonzalez-Maeso</surname><given-names>J.</given-names></name><name><surname>Yuen</surname><given-names>T.</given-names></name><name><surname>Ebersole</surname><given-names>B. J.</given-names></name><name><surname>Wurmbach</surname><given-names>E.</given-names></name><name><surname>Lira</surname><given-names>A.</given-names></name><name><surname>Zhou</surname><given-names>M.</given-names></name><etal/></person-group> (<year>2003</year>). <article-title>Transcriptome fingerprints distinguish hallucinogenic and nonhallucinogenic 5-hydroxytryptamine 2A receptor agonist effects in mouse somatosensory cortex.</article-title>
<source><italic>J. Neurosci.</italic></source>
<volume>23</volume>
<fpage>8836</fpage>&#x02013;<lpage>8843</lpage>.<pub-id pub-id-type="pmid">14523084</pub-id></mixed-citation></ref><ref id="B21"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gresch</surname><given-names>P. J.</given-names></name><name><surname>Smith</surname><given-names>R. L.</given-names></name><name><surname>Barrett</surname><given-names>R. J.</given-names></name><name><surname>Sanders-Bush</surname><given-names>E.</given-names></name></person-group> (<year>2005</year>). <article-title>Behavioral tolerance to lysergic acid diethylamide is associated with reduced serotonin-2A receptor signaling in rat cortex.</article-title>
<source><italic>Neuropsychopharmacology</italic></source>
<volume>30</volume>
<fpage>1693</fpage>&#x02013;<lpage>1702</lpage>. <pub-id pub-id-type="doi">10.1038/sj.npp.1300711</pub-id><pub-id pub-id-type="pmid">15756304</pub-id></mixed-citation></ref><ref id="B22"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Grunblatt</surname><given-names>E.</given-names></name><name><surname>Bartl</surname><given-names>J.</given-names></name><name><surname>Zehetmayer</surname><given-names>S.</given-names></name><name><surname>Ringel</surname><given-names>T. M.</given-names></name><name><surname>Bauer</surname><given-names>P.</given-names></name><name><surname>Riederer</surname><given-names>P.</given-names></name><etal/></person-group> (<year>2009</year>). <article-title>Gene expression as peripheral biomarkers for sporadic Alzheimer&#x02019;s disease.</article-title>
<source><italic>J. Alzheimers Dis.</italic></source>
<volume>16</volume>
<fpage>627</fpage>&#x02013;<lpage>634</lpage>. <pub-id pub-id-type="doi">10.3233/JAD-2009-0996</pub-id><pub-id pub-id-type="pmid">19276557</pub-id></mixed-citation></ref><ref id="B23"><mixed-citation publication-type="journal"><collab>GTExPortal</collab> (<year>2017</year>). <source><italic>The Genotype-Tissue Expression (GTEx) Project [Online]</italic>.</source> Available at: <ext-link ext-link-type="uri" xlink:href="https://gtexportal.org">https://gtexportal.org</ext-link>
<comment>[accessed December 4, 2017]</comment>.</mixed-citation></ref><ref id="B24"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hysek</surname><given-names>C. M.</given-names></name><name><surname>Ineichen</surname><given-names>M.</given-names></name><name><surname>Nicola</surname><given-names>V. G.</given-names></name><name><surname>Simmler</surname><given-names>L. D.</given-names></name><name><surname>Liechti</surname><given-names>M. E.</given-names></name></person-group> (<year>2010</year>). <article-title>Role of the norepinephrine uptake transporter in the mechanism of action of MDMA (Ecstasy).</article-title>
<source><italic>Eur. Neuropsychopharmacol.</italic></source>
<volume>20</volume>
<issue>S240</issue>
<pub-id pub-id-type="doi">10.1016/s0924-977x(10)70296-0</pub-id></mixed-citation></ref><ref id="B25"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Inoue</surname><given-names>M.</given-names></name><name><surname>Okazaki</surname><given-names>T.</given-names></name><name><surname>Kitazono</surname><given-names>T.</given-names></name><name><surname>Mizushima</surname><given-names>M.</given-names></name><name><surname>Omata</surname><given-names>M.</given-names></name><name><surname>Ozaki</surname><given-names>S.</given-names></name></person-group> (<year>2011</year>). <article-title>Regulation of antigen-specific CTL and Th1 cell activation through 5-Hydroxytryptamine 2A receptor.</article-title>
<source><italic>Int. Immunopharmacol.</italic></source>
<volume>11</volume>
<fpage>67</fpage>&#x02013;<lpage>73</lpage>. <pub-id pub-id-type="doi">10.1016/j.intimp.2010.10.007</pub-id><pub-id pub-id-type="pmid">20971187</pub-id></mixed-citation></ref><ref id="B26"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kraehenmann</surname><given-names>R.</given-names></name><name><surname>Pokorny</surname><given-names>D.</given-names></name><name><surname>Vollenweider</surname><given-names>L.</given-names></name><name><surname>Preller</surname><given-names>K. H.</given-names></name><name><surname>Pokorny</surname><given-names>T.</given-names></name><name><surname>Seifritz</surname><given-names>E.</given-names></name><etal/></person-group> (<year>2017</year>). <article-title>Dreamlike effects of LSD on waking imagery in humans depend on serotonin 2A receptor activation.</article-title>
<source><italic>Psychopharmacology</italic></source>
<volume>234</volume>
<fpage>2031</fpage>&#x02013;<lpage>2046</lpage>. <pub-id pub-id-type="doi">10.1007/s00213-017-4610-0</pub-id><pub-id pub-id-type="pmid">28386699</pub-id></mixed-citation></ref><ref id="B27"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lebedev</surname><given-names>A. V.</given-names></name><name><surname>Kaelen</surname><given-names>M.</given-names></name><name><surname>Lovden</surname><given-names>M.</given-names></name><name><surname>Nilsson</surname><given-names>J.</given-names></name><name><surname>Feilding</surname><given-names>A.</given-names></name><name><surname>Nutt</surname><given-names>D. J.</given-names></name><etal/></person-group> (<year>2016</year>). <article-title>LSD-induced entropic brain activity predicts subsequent personality change.</article-title>
<source><italic>Hum. Brain Mapp.</italic></source>
<volume>37</volume>
<fpage>3203</fpage>&#x02013;<lpage>3213</lpage>. <pub-id pub-id-type="doi">10.1002/hbm.23234</pub-id><pub-id pub-id-type="pmid">27151536</pub-id></mixed-citation></ref><ref id="B28"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liechti</surname><given-names>M. E.</given-names></name></person-group> (<year>2017</year>). <article-title>Modern clinical research on LSD.</article-title>
<source><italic>Neuropsychopharmacology</italic></source>
<pub-id pub-id-type="doi">10.1002/jcla.22265</pub-id>
<comment>[Epub ahead of print]</comment>.</mixed-citation></ref><ref id="B29"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liechti</surname><given-names>M. E.</given-names></name><name><surname>Dolder</surname><given-names>P. C.</given-names></name><name><surname>Schmid</surname><given-names>Y.</given-names></name></person-group> (<year>2017</year>). <article-title>Alterations in conciousness and mystical-type experiences after acute LSD in humans.</article-title>
<source><italic>Psychopharmacology</italic></source>
<volume>234</volume>
<fpage>1499</fpage>&#x02013;<lpage>1510</lpage>. <pub-id pub-id-type="doi">10.1007/s00213-016-4453-0</pub-id><pub-id pub-id-type="pmid">27714429</pub-id></mixed-citation></ref><ref id="B30"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Luykx</surname><given-names>J. J.</given-names></name><name><surname>Olde Loohuis</surname><given-names>L. M.</given-names></name><name><surname>Neeleman</surname><given-names>M.</given-names></name><name><surname>Strengman</surname><given-names>E.</given-names></name><name><surname>Bakker</surname><given-names>S. C.</given-names></name><name><surname>Lentjes</surname><given-names>E.</given-names></name><etal/></person-group> (<year>2016</year>). <article-title>Peripheral blood gene expression profiles linked to monoamine metabolite levels in cerebrospinal fluid.</article-title>
<source><italic>Transl. Psychiatry</italic></source>
<volume>6</volume>:<issue>e983</issue>
<pub-id pub-id-type="doi">10.1038/tp.2016.245</pub-id></mixed-citation></ref><ref id="B31"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Maple</surname><given-names>A. M.</given-names></name><name><surname>Zhao</surname><given-names>X.</given-names></name><name><surname>Elizalde</surname><given-names>D. I.</given-names></name><name><surname>McBride</surname><given-names>A. K.</given-names></name><name><surname>Gallitano</surname><given-names>A. L.</given-names></name></person-group> (<year>2015</year>). <article-title>Htr2a expression responds rapidly to environmental stimuli in an Egr3-dependent manner.</article-title>
<source><italic>ACS Chem. Neurosci.</italic></source>
<volume>6</volume>
<fpage>1137</fpage>&#x02013;<lpage>1142</lpage>. <pub-id pub-id-type="doi">10.1021/acschemneuro.5b00031</pub-id><pub-id pub-id-type="pmid">25857407</pub-id></mixed-citation></ref><ref id="B32"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mohr</surname><given-names>S.</given-names></name><name><surname>Liew</surname><given-names>C. C.</given-names></name></person-group> (<year>2007</year>). <article-title>The peripheral-blood transcriptome: new insights into disease and risk assessment.</article-title>
<source><italic>Trends Mol. Med.</italic></source>
<volume>13</volume>
<fpage>422</fpage>&#x02013;<lpage>432</lpage>. <pub-id pub-id-type="doi">10.1016/j.molmed.2007.08.003</pub-id><pub-id pub-id-type="pmid">17919976</pub-id></mixed-citation></ref><ref id="B33"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moreno</surname><given-names>J. L.</given-names></name><name><surname>Holloway</surname><given-names>T.</given-names></name><name><surname>Albizu</surname><given-names>L.</given-names></name><name><surname>Sealfon</surname><given-names>S. C.</given-names></name><name><surname>Gonzalez-Maeso</surname><given-names>J.</given-names></name></person-group> (<year>2011</year>). <article-title>Metabotropic glutamate mGlu2 receptor is necessary for the pharmacological and behavioral effects induced by hallucinogenic 5-HT2A receptor agonists.</article-title>
<source><italic>Neurosci. Lett.</italic></source>
<volume>493</volume>
<fpage>76</fpage>&#x02013;<lpage>79</lpage>. <pub-id pub-id-type="doi">10.1016/j.neulet.2011.01.046</pub-id><pub-id pub-id-type="pmid">21276828</pub-id></mixed-citation></ref><ref id="B34"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nichols</surname><given-names>C. D.</given-names></name><name><surname>Garcia</surname><given-names>E. E.</given-names></name><name><surname>Sanders-Bush</surname><given-names>E.</given-names></name></person-group> (<year>2003</year>). <article-title>Dynamic changes in prefrontal cortex gene expression following lysergic acid diethylamide administration.</article-title>
<source><italic>Brain Res. Mol. Brain Res.</italic></source>
<volume>111</volume>
<fpage>182</fpage>&#x02013;<lpage>188</lpage>. <pub-id pub-id-type="doi">10.1016/S0169-328X(03)00029-9</pub-id><pub-id pub-id-type="pmid">12654518</pub-id></mixed-citation></ref><ref id="B35"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nichols</surname><given-names>C. D.</given-names></name><name><surname>Sanders-Bush</surname><given-names>E.</given-names></name></person-group> (<year>2002</year>). <article-title>A single dose of lysergic acid diethylamide influences gene expression patterns within the mammalian brain.</article-title>
<source><italic>Neuropsychopharmacology</italic></source>
<volume>26</volume>
<fpage>634</fpage>&#x02013;<lpage>642</lpage>. <pub-id pub-id-type="doi">10.1016/S0893-133X(01)00405-5</pub-id><pub-id pub-id-type="pmid">11927188</pub-id></mixed-citation></ref><ref id="B36"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nichols</surname><given-names>C. D.</given-names></name><name><surname>Sanders-Bush</surname><given-names>E.</given-names></name></person-group> (<year>2004</year>). <article-title>Molecular genetic responses to lysergic acid diethylamide include transcriptional activation of MAP kinase phosphatase-1, C/EBP-beta and ILAD-1, a novel gene with homology to arrestins.</article-title>
<source><italic>J. Neurochem.</italic></source>
<volume>90</volume>
<fpage>576</fpage>&#x02013;<lpage>584</lpage>. <pub-id pub-id-type="doi">10.1111/j.1471-4159.2004.02515.x</pub-id><pub-id pub-id-type="pmid">15255935</pub-id></mixed-citation></ref><ref id="B37"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nichols</surname><given-names>D. E.</given-names></name></person-group> (<year>2016</year>). <article-title>Psychedelics.</article-title>
<source><italic>Pharmacol. Rev.</italic></source>
<volume>68</volume>
<fpage>264</fpage>&#x02013;<lpage>355</lpage>. <pub-id pub-id-type="doi">10.1124/pr.115.011478</pub-id><pub-id pub-id-type="pmid">26841800</pub-id></mixed-citation></ref><ref id="B38"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Passie</surname><given-names>T.</given-names></name><name><surname>Halpern</surname><given-names>J. H.</given-names></name><name><surname>Stichtenoth</surname><given-names>D. O.</given-names></name><name><surname>Emrich</surname><given-names>H. M.</given-names></name><name><surname>Hintzen</surname><given-names>A.</given-names></name></person-group> (<year>2008</year>). <article-title>The pharmacology of lysergic acid diethylamide: a review.</article-title>
<source><italic>CNS Neurosci. Ther.</italic></source>
<volume>14</volume>
<fpage>295</fpage>&#x02013;<lpage>314</lpage>. <pub-id pub-id-type="doi">10.1111/j.1755-5949.2008.00059.x</pub-id><pub-id pub-id-type="pmid">19040555</pub-id></mixed-citation></ref><ref id="B39"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Preller</surname><given-names>K. H.</given-names></name><name><surname>Herdener</surname><given-names>M.</given-names></name><name><surname>Pokorny</surname><given-names>T.</given-names></name><name><surname>Planzer</surname><given-names>A.</given-names></name><name><surname>Kraehenmann</surname><given-names>R.</given-names></name><name><surname>St&#x000e4;mpfli</surname><given-names>P.</given-names></name><etal/></person-group> (<year>2017</year>). <article-title>The fabric of meaning and subjective effects in LSD-induced states depend on serotonin 2A receptor activation.</article-title>
<source><italic>Curr. Biol.</italic></source>
<volume>27</volume>
<fpage>451</fpage>&#x02013;<lpage>457</lpage>. <pub-id pub-id-type="doi">10.1016/j.cub.2016.12.030</pub-id><pub-id pub-id-type="pmid">28132813</pub-id></mixed-citation></ref><ref id="B40"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ramakers</surname><given-names>C.</given-names></name><name><surname>Ruijter</surname><given-names>J. M.</given-names></name><name><surname>Deprez</surname><given-names>R. H.</given-names></name><name><surname>Moorman</surname><given-names>A. F.</given-names></name></person-group> (<year>2003</year>). <article-title>Assumption-free analysis of quantitative real-time polymerase chain reaction (PCR) data.</article-title>
<source><italic>Neurosci. Lett.</italic></source>
<volume>339</volume>
<fpage>62</fpage>&#x02013;<lpage>66</lpage>. <pub-id pub-id-type="doi">10.1016/S0304-3940(02)01423-4</pub-id><pub-id pub-id-type="pmid">12618301</pub-id></mixed-citation></ref><ref id="B41"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rickli</surname><given-names>A.</given-names></name><name><surname>Moning</surname><given-names>O. D.</given-names></name><name><surname>Hoener</surname><given-names>M. C.</given-names></name><name><surname>Liechti</surname><given-names>M. E.</given-names></name></person-group> (<year>2016</year>). <article-title>Receptor interaction profiles of novel psychoactive tryptamines compared with classic hallucinogens.</article-title>
<source><italic>Eur. Neuropsychopharmacol.</italic></source>
<volume>26</volume>
<fpage>1327</fpage>&#x02013;<lpage>1337</lpage>. <pub-id pub-id-type="doi">10.1016/j.euroneuro.2016.05.001</pub-id><pub-id pub-id-type="pmid">27216487</pub-id></mixed-citation></ref><ref id="B42"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rivera-Baltanas</surname><given-names>T.</given-names></name><name><surname>Olivares</surname><given-names>J. M.</given-names></name><name><surname>Martinez-Villamarin</surname><given-names>J. R.</given-names></name><name><surname>Fenton</surname><given-names>E. Y.</given-names></name><name><surname>Kalynchuk</surname><given-names>L. E.</given-names></name><name><surname>Caruncho</surname><given-names>H. J.</given-names></name></person-group> (<year>2014</year>). <article-title>Serotonin 2A receptor clustering in peripheral lymphocytes is altered in major depression and may be a biomarker of therapeutic efficacy.</article-title>
<source><italic>J. Affect. Disord.</italic></source>
<volume>163</volume>
<fpage>47</fpage>&#x02013;<lpage>55</lpage>. <pub-id pub-id-type="doi">10.1016/j.jad.2014.03.011</pub-id><pub-id pub-id-type="pmid">24836087</pub-id></mixed-citation></ref><ref id="B43"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rollins</surname><given-names>B.</given-names></name><name><surname>Martin</surname><given-names>M. V.</given-names></name><name><surname>Morgan</surname><given-names>L.</given-names></name><name><surname>Vawter</surname><given-names>M. P.</given-names></name></person-group> (<year>2010</year>). <article-title>Analysis of whole genome biomarker expression in blood and brain.</article-title>
<source><italic>Am. J. Med. Genet. B Neuropsychiatr. Genet.</italic></source>
<volume>153B</volume>, <fpage>919</fpage>&#x02013;<lpage>936</lpage>. <pub-id pub-id-type="doi">10.1002/ajmg.b.31062</pub-id><pub-id pub-id-type="pmid">20127885</pub-id></mixed-citation></ref><ref id="B44"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schmid</surname><given-names>Y.</given-names></name><name><surname>Enzler</surname><given-names>F.</given-names></name><name><surname>Gasser</surname><given-names>P.</given-names></name><name><surname>Grouzmann</surname><given-names>E.</given-names></name><name><surname>Preller</surname><given-names>K. H.</given-names></name><name><surname>Vollenweider</surname><given-names>F. X.</given-names></name><etal/></person-group> (<year>2015</year>). <article-title>Acute effects of lysergic acid diethylamide in healthy subjects.</article-title>
<source><italic>Biol. Psychiatry</italic></source>
<volume>78</volume>
<fpage>544</fpage>&#x02013;<lpage>553</lpage>. <pub-id pub-id-type="doi">10.1016/j.biopsych.2014.11.015</pub-id><pub-id pub-id-type="pmid">25575620</pub-id></mixed-citation></ref><ref id="B45"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stefulj</surname><given-names>J.</given-names></name><name><surname>Jernej</surname><given-names>B.</given-names></name><name><surname>Cicin-Sain</surname><given-names>L.</given-names></name><name><surname>Rinner</surname><given-names>I.</given-names></name><name><surname>Schauenstein</surname><given-names>K.</given-names></name></person-group> (<year>2000</year>). <article-title>mRNA expression of serotonin receptors in cells of the immune tissues of the rat.</article-title>
<source><italic>Brain Behav. Immun.</italic></source>
<volume>14</volume>
<fpage>219</fpage>&#x02013;<lpage>224</lpage>. <pub-id pub-id-type="doi">10.1006/brbi.1999.0579</pub-id><pub-id pub-id-type="pmid">10970681</pub-id></mixed-citation></ref><ref id="B46"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Steuer</surname><given-names>A. E.</given-names></name><name><surname>Poetzsch</surname><given-names>M.</given-names></name><name><surname>Stock</surname><given-names>L.</given-names></name><name><surname>Eisenbeiss</surname><given-names>L.</given-names></name><name><surname>Schmid</surname><given-names>Y.</given-names></name><name><surname>Liechti</surname><given-names>M. E.</given-names></name><etal/></person-group> (<year>2016</year>). <article-title>Development and validation of an ultra-fast and sensitive microflow liquid chromatography-tandem mass spectrometry (MFLC-MS/MS) method for quantification of LSD and its metabolites in plasma and application to a controlled LSD administration study in humans.</article-title>
<source><italic>Drug Test. Anal.</italic></source>
<volume>9</volume>
<fpage>788</fpage>&#x02013;<lpage>797</lpage>. <pub-id pub-id-type="doi">10.1002/dta.2042</pub-id><pub-id pub-id-type="pmid">27422082</pub-id></mixed-citation></ref><ref id="B47"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Strajhar</surname><given-names>P.</given-names></name><name><surname>Schmid</surname><given-names>Y.</given-names></name><name><surname>Liakoni</surname><given-names>E.</given-names></name><name><surname>Dolder</surname><given-names>P. C.</given-names></name><name><surname>Rentsch</surname><given-names>K. M.</given-names></name><name><surname>Kratschmar</surname><given-names>D. V.</given-names></name><etal/></person-group> (<year>2016</year>). <article-title>Acute effects of lysergic acid diethylamide on circulating steroid levels in healthy subjects.</article-title>
<source><italic>J. Neuroendocrinol.</italic></source>
<volume>28</volume>:<issue>12374</issue>
<pub-id pub-id-type="doi">10.1111/jne.12374</pub-id></mixed-citation></ref><ref id="B48"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sullivan</surname><given-names>P. F.</given-names></name><name><surname>Fan</surname><given-names>C.</given-names></name><name><surname>Perou</surname><given-names>C. M.</given-names></name></person-group> (<year>2006</year>). <article-title>Evaluating the comparability of gene expression in blood and brain.</article-title>
<source><italic>Am. J. Med. Genet. B Neuropsychiatr. Genet.</italic></source>
<volume>141B</volume>, <fpage>261</fpage>&#x02013;<lpage>268</lpage>. <pub-id pub-id-type="doi">10.1002/ajmg.b.30272</pub-id><pub-id pub-id-type="pmid">16526044</pub-id></mixed-citation></ref><ref id="B49"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tagliazucchi</surname><given-names>E.</given-names></name><name><surname>Roseman</surname><given-names>L.</given-names></name><name><surname>Kaelen</surname><given-names>M.</given-names></name><name><surname>Orban</surname><given-names>C.</given-names></name><name><surname>Muthukumaraswamy</surname><given-names>S. D.</given-names></name><name><surname>Murphy</surname><given-names>K.</given-names></name><etal/></person-group> (<year>2016</year>). <article-title>Increased global functional connectivity correlates with LSD-induced ego dissolution.</article-title>
<source><italic>Curr. Biol.</italic></source>
<volume>26</volume>
<fpage>1043</fpage>&#x02013;<lpage>1050</lpage>. <pub-id pub-id-type="doi">10.1016/j.cub.2016.02.010</pub-id><pub-id pub-id-type="pmid">27085214</pub-id></mixed-citation></ref><ref id="B50"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vandesompele</surname><given-names>J.</given-names></name><name><surname>De Preter</surname><given-names>K.</given-names></name><name><surname>Pattyn</surname><given-names>F.</given-names></name><name><surname>Poppe</surname><given-names>B.</given-names></name><name><surname>Van Roy</surname><given-names>N.</given-names></name><name><surname>De Paepe</surname><given-names>A.</given-names></name><etal/></person-group> (<year>2002</year>). <article-title>Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes.</article-title>
<source><italic>Genome Biol.</italic></source>
<volume>3</volume>
<issue>RESEARCH0034</issue>
<pub-id pub-id-type="doi">10.1186/gb-2002-3-7-research0034</pub-id></mixed-citation></ref><ref id="B51"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vizeli</surname><given-names>P.</given-names></name><name><surname>Liechti</surname><given-names>M. E.</given-names></name></person-group> (<year>2017</year>). <article-title>Safety pharmacology of acute MDMA administration in healthy subjects.</article-title>
<source><italic>J. Psychopharmacol.</italic></source>
<volume>31</volume>
<fpage>576</fpage>&#x02013;<lpage>588</lpage>. <pub-id pub-id-type="doi">10.1177/0269881117691569</pub-id><pub-id pub-id-type="pmid">28443695</pub-id></mixed-citation></ref><ref id="B52"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wacker</surname><given-names>D.</given-names></name><name><surname>Wang</surname><given-names>S.</given-names></name><name><surname>McCorvy</surname><given-names>J. D.</given-names></name><name><surname>Betz</surname><given-names>R. M.</given-names></name><name><surname>Venkatakrishnan</surname><given-names>A. J.</given-names></name><name><surname>Levit</surname><given-names>A.</given-names></name><etal/></person-group> (<year>2017</year>). <article-title>Crystal structure of an LSD-bound human serotonin receptor.</article-title>
<source><italic>Cell</italic></source>
<volume>168</volume>
<issue>377.e12</issue>&#x02013;<issue>389.e12</issue>
<pub-id pub-id-type="doi">10.1016/j.cell.2016.12.033</pub-id></mixed-citation></ref><ref id="B53"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yubero-Lahoz</surname><given-names>S.</given-names></name><name><surname>Kuypers</surname><given-names>K. P.</given-names></name><name><surname>Ramaekers</surname><given-names>J. G.</given-names></name><name><surname>Langohr</surname><given-names>K.</given-names></name><name><surname>Farre</surname><given-names>M.</given-names></name><name><surname>de la Torre</surname><given-names>R.</given-names></name></person-group> (<year>2015</year>). <article-title>Changes in serotonin transporter (5-HTT) gene expression in peripheral blood cells after MDMA intake.</article-title>
<source><italic>Psychopharmacology</italic></source>
<volume>232</volume>
<fpage>1921</fpage>&#x02013;<lpage>1929</lpage>. <pub-id pub-id-type="doi">10.1007/s00213-014-3827-4</pub-id><pub-id pub-id-type="pmid">25524139</pub-id></mixed-citation></ref></ref-list></back></article>